TriangleTINKS (NCT05634369)
TINKS trial for Relapsed/Refractory Pediatric Sarcoma (NCT05634369). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for bone and soft tissue sarcomas in children and young adults, ages 2 to 40, that have relapsed or not responded to treatment.
The idea: add natural killer cells to chemotherapy. Donor NK cells are grown in the lab and given by vein after the chemotherapy drugs gemcitabine and docetaxel, in 21 day cycles.
This phase 1 and 2 study plans 50 participants and looks at safety and six month progression free survival. At Nationwide Children's Hospital in Ohio, Bhuvana Setty leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.